publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
HER3-DXd
Changes in HER3 expression profiles between primary and recurrent gynecological cancers
HER3-DXd
Quantitative analysis of drug distribution in heterogeneous tissues using dual-stacking capillary electrophoresis-mass spectrometry
T-DXd
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
T-DXd
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: A DESTINY-Breast01 subgroup analysis
Edoxaban
Effect of edoxaban, F-Xa-directed oral anticoagulant on spontaneous thrombolytic activity in Apoe-/- and Ldlr-/- double knockout mice
T-DXd
Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: Exploratory cohort results in a phase II trial
Edoxaban
Edoxaban in cardiovascular medicine from scientific evidence to clinical practice
T-DXd
Effect of trastuzumab deruxtecan on QT/QTC interval and pharmacokinetics in HER2-positive or HER2-low metastatic/unresectable breast cancer
HER3-DXd
Population pharmacokinetics of patritumab deruxtecan in patients with solid tumors
Pexidartinib
Pexidartinib provides modest pain relief in patients with tenosynovial giant cell tumor: Results from ENLIVEN